Today, CDC Director Rochelle P. Walensky, M.D., M.P.H., signed a decision letter recommending that Novavax’s COVID-19 vaccination be utilised as a secondary series option for adolescents aged 12 to 17. This advice follows the FDA’s approval of the vaccine for this age range for emergency use.
Novavax’s COVID-19 vaccine, which is currently accessible, is an essential instrument in the pandemic and offers teenagers with a more familiar form of COVID-19 vaccine technology. Having a variety of vaccinations provides the public, governments, and vaccine providers with greater alternatives and flexibility.
Also Read: Covid case update: India reports 6,168 new cases
The COVID-19 vaccine from Novavax contains harmless COVID-19 viral proteins as well as an adjuvant, which aids the immune system’s future response to the virus. Vaccines that employ protein subunit technology, such as the Novavax COVID-19 vaccine, have been used in the United States for more than 30 years, beginning with the first approved hepatitis B vaccination.
Other protein subunit vaccines used in the United States today include those to protect against influenza and whooping cough (acellular pertussis).
Explore the profound effects of excessive screen time on your child’s behavior and development. Discover…
Discover how simple daily changes in your diet and lifestyle can significantly improve your heart…
This article explores the common misconception that brain tumours primarily affect older adults, revealing the…
The first-ever ovarian cancer vaccine is poised to change the landscape of women's health by…
As dengue and chikungunya cases rise in Delhi during the monsoon season, understanding prevention strategies…
Skincare is a significant concern for women (and increasingly, men), with the quest for perfect,…